Paclitaxel 30 Mg/5 Ml Fresenius, Paclitaxel 100 Mg/16,7 Ml Fresenius, Paclitaxel 300 Mg/50 Ml Fresenius, 30 mg/5 ml, 100 mg/16,7 ml, 300 mg/50 ml Concentrate for solution for infusion
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of advanced ovarian, breast, and non-small cell lung cancer.
Dosage (summary)
175 mg/mu00b2 IV over 3 hours every 3 weeks; adjust for hepatic impairment.
Special Populations
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; may cause fetal harm.
Key Drug Interactions
- Ketoconazole may inhibit metabolism
- Doxorubicin may increase plasma levels
Contraindications
- Severe hypersensitivity to paclitaxel
- Baseline neutrophils < 1500/mmu00b3
- Pregnancy
- Lactation
Common side effects
- Neutropenia
- Peripheral neuropathy
- Hypersensitivity reactions
- Nausea
- Vomiting
Counselling Points
- Avoid pregnancy during treatment
- Monitor for signs of infection
- Do not drive if affected by side effects
Serious warnings
- Severe hypersensitivity reactions
- Bone marrow suppression
- Cardiovascular events
The Paclitaxel 30 Mg/5 Ml Fresenius, Paclitaxel 100 Mg/16,7 Ml Fresenius, Paclitaxel 300 Mg/50 Ml Fresenius, 30 mg/5 ml, 100 mg/16,7 ml, 300 mg/50 ml Concentrate for solution for infusion professional information leaflet below is the property of Fresenius Kabi South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.